相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models
Melanie G. Cornejo et al.
BLOOD (2009)
JAK3: A two-faced player in hematological disorders
Melanie G. Cornejo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
The JAK kinase inhibitor CP-690,550 supresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation
Taghi Manshouri et al.
CANCER SCIENCE (2008)
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation
Srdan Verstovsek et al.
CLINICAL CANCER RESEARCH (2008)
In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2V617F allele
Amos Gaikwad et al.
EXPERIMENTAL HEMATOLOGY (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Polycythemia vera is not initiated by JAK2(V17F) mutation
Roberto H. Nussenzveig et al.
EXPERIMENTAL HEMATOLOGY (2007)
Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, atiprimod
Sweeta R. Choudhari et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Virginia M. Zaleskas et al.
PLOS ONE (2006)
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Denise K. Walters et al.
CANCER CELL (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
IS Lucet et al.
BLOOD (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
XH Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Identification of an acquired JAK2 mutation in Polycythemia vera
RX Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
The chronic myeloproliferative disorders: Clonality and clinical heterogeneity
JL Spivak
SEMINARS IN HEMATOLOGY (2004)
分享论文
